SUBJECT INDEX

Acetate
  dialysate and adrenergic receptor responsiveness, 111
  haemodialysis symptoms, 235
  relationship to haemodialysis symptoms, 166
Acid/base, calcium carbonate in haemo-
dialysis patients, 83
Acquired immune deficiency syndrome,
  infection in a transplant patient, 645
Acute renal failure, see Renal failure, acute
Adrenal function in nephrotic syndrome,
  1062
Adrenergic receptors
  alpha receptors during dialysis, 259
  myocardial receptors responses in uraemia, 901
  responsiveness in uraemia, acetate and bicarbonate dialysis, 111
Adriamycin, experimental glomerulo-
nephritis, 927
Age, risk factor for peritonitis during CAPD, 401
Albumin, response to calcium carbonate in
  haemodialysis patients, 83
Alcoholism, risk factor for rhabdomyolysis
  induced acute renal failure, 1091
Alpha-Tocopherol, role in haemolysis during
dialysis, 1139
Alpha-1-microglobulin
  as an index of glomerular filtration rate in chronic renal failure, 1173
  in tubular reabsorption, 1173
Alport's syndrome
  Goodpasture antigen, 742
  pregnancy, 441
Aluminium
  beneficial effect of magnesium carbonate as a phosphate binder, 1229
  effects of phosphate binders on bone content of aluminium, 369
  HLA link with dialysis encephalopathy, 360
  Aluminium (continued)
    in haemodialysis, 276
    indication for DFO test, 388
    microcytic anaemia, 101, 374
    mobilization by desferrioxamine, 101
    osteomalacia and 1,25(OH)2D3 receptor status, 382
    overload due to phosphate binders, 363
    removal by PAN and combined cuprophan and charcoal, 386
    renal osteodystrophy in patients treated by haemofiltration, 363
    spinal fluid values in dialysis encephalopathy, 354
    tissue concentration in dialysis patients, 349
    toxicity in patients with analgesic nephro-
      pathy, 997
    use of water softeners, 369
Amino acid metabolism, turnover studies in
  renal failure, 116
Amino acids, effect of infusions on glome-
  rular filtration rate, 917, 1049
Aminoglycosides
  nephrotoxicity, 959, 1033
  related nephrotoxicity risk factors, 966
Amyloid, deposition in long term haemo-
  dialysis patients, 131, 136, 241
Amyloidosis
  peritoneal protein loss during CAPD, 405
  pregnancy in FMF associated amyloidosis, 478
  role of polycrylonitrile membranes, 223
Anaemia
  aluminium induced microcytic anaemia, 374
  effect of biotin supplements, 255
  microcytic in aluminium intoxication, 101, 374
Analgesic nephropathy, 977
  aluminium intoxication, 997
  geographical distribution, 979
  phenacetin, 987
Anaphylatoxin, temperature dependence during dialysis, 216
Angiotensin
effect in isolated perfused rat kidney, 871
influence on prostaglandin synthesis by isolated glomeruli, 858
inhibition by Captopril in prostaglandin study, 1045
resistance in pregnancy, 824
Antibodies
Fc receptor blocking antibodies, 809
idiotype in IgA nephropathy, 705
Antibody responses, minimal change nephropathy, 815
Anticoagulation, sodium citrate in haemodialysis, 325
Anti-diuretic hormone
prostaglandin excretion in ADH suppressed dogs, 1054
prostaglandins, 1045
Antigen, Goodpasture in Alport's syndrome, 742
Arthropathy, complication of long-term haemodialysis, 131
Aspergillus peritonitis, 397
Aspirin, prostaglandins, 1045
Autonomic nervous system, assessment in haemodialysis patients, 266
Basal metabolic rate, haemodialysis effects, 106
Bicarbonate
dialysate and adrenergic receptor responsiveness, 111
relationship to haemodialysis symptoms, 166
Biocompatibility
acute renal failure, 202
chronic renal failure, 202, 207, 212
dialyser reuse, 173
effect on protein metabolism, 223
haemodialysis associated symptoms, 163
membranes, 223
T cell subset change, 196
Blood
brain barrier, permeability studies on dialysis encephalopathy, 354
transfusion
effect on leucocyte functions as assessed by superoxide production, 247
Blood (continued)
transfusion (continued)
role of Fc receptor blocking factors on transplant effect, 809
transplant survival, 589
volume, during haemodialysis in children, 847
Bone
biopsy, in patients treated by haemofiltration, 363
formation rate, GLA protein as an indicator, 1218
Brush border vesicles, sodium-hydrogen exchange, 865
CAPD (continuous ambulatory peritoneal dialysis)
amino acid containing solutions, 421
catheter displacement, 426
chromium accumulation, 270
fungal peritonitis, 397
impaired lymphocyte function, 932
paediatric registry report details, 70–72
pancreatic β cell secretory function, 1067
peritoneal protein losses and clearances, 405
protein losses during peritonitis, 421
risk factors for peritonitis, 401
selenium deficiency, 1134
short catheters, 426
trace elements in plasma, 410
Calcium
diphosphonate therapy after transplantation, 1233
interaction with sodium in hypertensive patients, 884
intestinal absorption following an oxalate load, 1163
role of 1,25(OH)2D3 after transplantation, 1212
carbonate
protein metabolic effects, 83
risk factors for vascular calcification, 88
stone disease, water quality and thiazide treatment depends on oxalate restriction, 1159
Candida peritonitis, 397
Captopril, inhibition of angiotensin in prostaglandin study, 1045
Carbohydrate metabolism
carnitine containing dialysate, 127
Carbohydrate metabolism (continued)
thyroid function tests in chronic renal
failure, 953
Cardiomyopathy
left ventricular function in uraemic
cardiomyopathy, 906
selenium deficiency, 1134
Cardiovascular
adrenergic receptor responsiveness and
bicarbonate or acetate dialysis, 111
changes in pregnancy, 823
complications in polycystic renal disease, 910
instability during haemodialysis, 231
left ventricular function in uraemic
cardiomyopathy, 906
Carnitine, changes in post-dialysis glucose
intolerance, 127
Carpal Tunnel syndrome, complication of
long-term haemodialysis, 136
Casein, progression of renal failure in
experimental renal disease, 921
Catecholamines
effect on left ventricular function in
uraemic cardiomyopathy, 906
influence on prostaglandin synthesis by
isolated glomeruli, 858
in patients with dialysis-induced hypotension, 266
pregnancy, 825
Catheters, experience with short CAPD
catheters, 426
Cellular immunity
impaired in chronic renal failure, 937
infection complications, 937
minimal change nephropathy, 815
Cellulose acetate, biocompatibility, 173
Centre effect in renal transplantation, 639
Cephalosporins, risk factors for aminoglycoside toxicity, 969
Chemiluminescence
during membrane biocompatibility, 207
effect of ultrafiltration rate on PMN, 223
leucocyte activation, 207
Children
acute renal failure, 1187, 1193
blood volume measurement during haemodialysis, 847
paediatric registry report, 55–79
single needle dialysis, 341
Cholesterol
chronic renal failure, 1129
Cholesterol (continued)
effect of L-carnitine in haemodialysis
patients, 121
Chromium
plasma values in CAPD and haemodialysis
patients, 270
plasma values in CAPD patients, 410
Chronic renal failure, see Renal failure, chronic
Circadian rhythm in plasma renin activity, 851
Cirrhosis, IgA nephropathy, 784
Cis-platinum, nephrotoxicity, 1087
Coagulation, low molecular weight heparin
for haemodialysis, 329
Complement
activation during dialysis, 196
activation in low temperature dialysis, 216
biocompatibility activation, 164
dialysis induced activation and effect of
nafamostat, 334
glomerular deposition in IgA nephropathy, 763
urinary excretion in membranous nephropathy, 790
Convective mass transport, 155
Copper in haemodialysis, 276
Cortisol, circadian rhythm in nephrotic
syndrome, 1062
Counselling
pregnancy in patients with renal disease, 444
pregnancy in patients with SLE, 449
Cuprophan
biocompatibility, 165, 173, 223
convective mass transport, 155
possible role in amyloidosis complicating
long-term haemodialysis, 136
T cell subset changes in dialysis, 196
Cyclo-oxygenase
in platelets before and after haemodialysis, 250
suppressor factor in uraemia, 250
Cyclosporin A
blood concentrations, 579
combined with retroplacental gamma
globulin, 619
conversion to azathioprine, 535, 571
diagnosis of nephrotoxicity with indium
labelled platelets, 1183
effects on creatinine clearance, 535
fine needle aspiration biopsy, 546, 579
Cyclosporin A (continued)
- glutathione-S-transferase excretion, 561
- infections, 571
- inhibition of gluconeogenesis, 556
- intrarenal deposits during nephrotoxicity, 546
- nephrotoxicity, 535, 540, 546, 571, 609, 1183
  - and factor VIII R antigen, 566
  - in heart transplant recipients, 551
  - histological studies, 540
  - nuclear magnetic resonance in acute rejection and nephrotoxicity, 609
- pharmacokinetics, 535
- plasma concentrations, 579
- therapeutic schedules, 579
- transplant survival, 591
- tubular proteinuria, 561

Cytomegalovirus
- immunization in transplant recipients, 630
- infection
  - diagnosis in transplant recipients, 655
  - Foscarnet treatment, 645
  - leucocytotoxins, 655
  - rheumatoid factor, 655
- urinary excretion in transplant patients, 1145

Delayed hypersensitivity, minimal change nephropathy, 815

Desferrioxamine
- aluminium mobilization, 101
- effect on iron metabolism, 374
- indication for DFO test, 388
- induced increase in plasma aluminium, 388

Developmental abnormalities, polycystic renal disease, 910

Diabetes
- insipidus,
  - lithium induced in a neonate, 1017
  - renal PGE₂-9-ketoreductase activity, 862
- mellitus
  - GFR response to protein load, 843
  - peritoneal protein loss during CAPD, 405
  - selection of patients for transplantation, 523
  - transplantation, 521

Dialysate
- carnitine effect on glucose intolerance, 127
- magnesium, 1229
- optimum magnesium concentration, 97
- temperature and anaphylatoxin release, 216

Dialysers, re-use, 173

Dialysis
- encephalopathy
  - linkage to HLA type, 360
  - spinal fluid aluminium concentrations, 354
- schedules
  - hypertonic haemodiafiltration, 308
  - six hours weekly, 312
- symptoms, hypertonic haemodiafiltration, 308

Diet
- effect of meat-free diet on 3 methylhistidine excretion, 1115
- effect of protein load on GFR, 843
- immune complexes in IgA nephropathy, 710
- interaction between sodium and calcium in hypertension, 884
- low protein prevents glomerular deposition in experimental nephropathy, 927
- protein quality and progression of experimental renal disease, 921
- protein restriction and proteinuria, 1083

Diphosphonate, therapy for post-transplant hypercalcaemia, 1233

Dobutamine, effect on left ventricular function in uraemic cardiomyopathy, 906

Drugs
- aminoglycoside nephrotoxicity, 959
- analgesic nephropathy, 977, 987
- glomerulopathy, 683

Eclampsia, pregnancy, 825

Endothelial cell antigens, transplant rejection, 627

Erythropoiesis, after renal transplantation, 651

Essential mixed cryoglobulinaemia, phagocytic cell function, 759

Ethylene oxide, haemodialysis reactions, 187, 223

Factor VIII related antigen, Cyclosporin A and nephrotoxicity, 566
Familial Mediterranean fever, pregnancy in patients with associated amyloidosis, 478
Fc receptor blocking antibodies, effect of blood transfusion, 809
Ferritin, aluminium overload and iron metabolism, 374
Fetal loss, systemic lupus erythematosus, 487
Fine needle aspiration biopsy
Cyclosporin A, 579
in Cyclosporin A nephrotoxicity, 546
transplant rejection, 627
Fistulas, see Vascular access
Flow cytometry in renal transplantation, 622
Foscarnet, CMV retinitis, 645
Free fatty acids
during haemodialysis, 321
heparin anticoagulation, 321
Fungal peritonitis, CAPD patients, 397
First use syndrome, complement activation, 164

Gentamicin, acute renal failure, 1008
GLA protein, effect of 1,25(OH)₂D₃ in uraemia, 1223

Glomerular
basement membrane
Goodpasture antigen in Alport’s syndrome, 742
studies in experimental glomerulonephritis, 1103
target antigens in Goodpasture’s syndrome, 746
capillary wall, experimental studies, 767
changes, experimentally induced mitomycin injury, 1020
filtration rate
Felodipine, 1037
increased by amino acid infusions, 1049
infusion of essential amino acids, 917
infusion of keto-analogues, 917
measurement of alpha-1-microglobulin in chronic renal failure, 1173
pre-eclampsia, 832
pregnancy, 465
prostaglandins, 1049

Glomerulonephritis
aetiology, 725
cationic IgG in membranous nephropathy, 773

Glomerulonephritis (continued)
complement deposition in IgA nephropathy, 763
drug induced, 683
experimental, 819, 1103
adriamycin induced, 927
drug induced, 688
studies of inherited glomerular properties, 767
glomerular IgA in cirrhosis, 784
heroin addiction, 778
immune responses in patients with minimal change nephropathy, 813
intradermal skin testing in the loin pain haematuria syndrome, 796
neo-antigen deposition, 819
pregnancy, 442, 473
in IgA nephropathy, 482
reduction in annual incidence of membranoproliferative GN in France, 730
solvent exposure and progressive disease, 725
urinary complement in membranous nephropathy, 790
Glomerulosclerosis, renal effects of pregnancy, 473
Glucagon
effect on RPF and GFR, 917
insulin response in uraemia, 1067
Glucose, dialysis induced intolerance, 127
Gluten, pathogenesis of IgA nephropathy, 710
Glutathione-S-transferase, excretion in Cyclosporin A treated rats, 561
Glycerol, acute renal failure, 1008
Gold, glomerulonephritis, 685
Goodpasture antigen, Alport’s syndrome, 742
Goodpasture’s syndrome
characterization of target antigens, 746
experimental rat model, 736
immunoabsorption, 736
Growth, children, paediatric registry report details, 75–78

Haemodiafiltration
convective mass transport, 156
hypertonic, 308
small and middle molecule clearances, 303
Haemodialysis
adrenergic receptor responsiveness, 111, 259
alpha-tocopherol and anaemia, 1139
aluminium
induced microcytic anaemia, 101, 374
removal after DFO, 386
toxicity, 101, 369, 374
in patients with analgesic nephropathy, 997
amino acid metabolism, 116
amyloid as a complication of long-term treatment, 136
amyloidosis as a long-term complication, 131
arteriovenous fistulas, 296
bone
aluminium, 369
GLA protein as an indicator of bone formation rates, 1218
chemiluminescence, 207
calcium carbonate and metabolic effects, 83
carnitine and glucose intolerance, 127
changes
in alpha-adrenoceptors, 259
in beta-adrenoceptors, 259
chromium transfer studies, 270
comparison
with haemodialfiltration, 303
with hypertonic haemodialfiltration, 308
DFO test for aluminium toxicity, 388
dialyser reuse, 173
disordered autonomic nervous system in hypotensive patients, 266
effect
of biotin supplements in anaemia, 255
of L-carnitine on lipid abnormalities, 121
effects
of iron overload on leucocyte function, 247
of iron overload on superoxide production, 247
energy turnover, 106
first use reactions, 237
free fatty acid and triglyceride concentration, 321
harmful effects of Vitamin C, 147
heparin versus epoprostenol as anticoagulant, 321
Haemodialysis (continued)
hypersensitivity reactions, 181, 187
hypotension, 229, 259
immune defect and lipid peroxidation, 139
impaired lymphocyte function, 932
induction of Interleukin I synthesis by cuprophan membranes, 192
insulin distribution volume in children, 847
interleukin, 158, 229
left ventricular function in uraemic cardiomyopathy, 906
leucocyte
activation, 207
elastase, 202, 212
leucopenia, 202, 212
lipid response to L-carnitine, 121
low
molecular weight heparin, 329
temperature and complement activation, 216
membrane biocompatibility, 196, 202, 207, 212
microcytic anaemia and aluminium intoxication, 101, 374
motor nerve conduction velocity, 1167
nafamstat as a suitable anticoagulant, 334
once weekly, 312
optimum magnesium concentration, 97
oxalate deposition, 147
pancreatic B cell secretory function, 1067
platelet function, 946
psychological disturbance in long-term patients, 142
recirculation, 296
risk factors for vascular calcification, 88
role of alpha-tocopherol in haemolysis, 1148
selenium deficiency, 1134
single needle device, 341
sodium citrate anticoagulation, 325
symptoms, 163, 230, 235
and blood volume measurements, 847
tissue concentrations of aluminium, 349
trace elements bound to plasma proteins, 276
urinary cytomegalovirus excretion, 1145
use of phosphate binders, 369
vibration sensory threshold, 1167
vitamin supplements, 147, 255
Yersina enterocolitica bacteremia, 283
Haemofiltration
- acute renal failure in neonates, 1187
- convective mass transport, 156
- hypertonic haemofiltration, 308
- renal osteodystrophy, 363

Haemolysis, role of alpha-tocopherol during haemodialysis, 1139

Haemolytic uraemic syndrome
- acute renal failure in children, 1193
- experimentally induced by mitomycin, 1020
- paediatric registry report details, 65–68

Heart transplantation, incidence of Cyclosporin A nephrotoxicity, 551

Henoch-Schönlein nephritis, glomerular complement deposition, 763

Heparin, low molecular weight for haemodialysis, 329

Hepatitis
- effect of vaccination on lymphocyte function, 941
- immunization protocols in dialysis patients, 1077
- seroprophylaxis in chronic renal failure patients, 1077
- transmission during parturition, 455
- vaccination schedules in uraemia, 941, 1073

Heroin, glomerulonephritis in addicts, 778

Heymann's nephritis, 692
- cellular regulation of autoantibody production, 805

HLA antigens
- linkage to dialysis encephalopathy, 360
- risk factors in aseptic bone necrosis, 660
- in transplantation, 587, 635

Hydrochlorothiazide, therapy in calcium stone disease depends on oxalate restriction, 1159

Hyperparathyroidism, relationship to $1,25(OH)_2D_3$ in early uraemia, 1124

Hypersensitivity reactions
- during haemodialysis, 181
- ethylene oxide, 187
- loin pain haematuria syndrome, 796

Hypertension
- blood volume measurements during dialysis, 847
- diurnal change in plasma renin activity, 851
- interaction between dietary sodium and calcium, 884

Hypertension (continued)
- malignant, IgA nephropathy, 875
- natriuresis in hypertensive pregnant patients, 493
- pregnancy, 450, 466, 515, 823
- changes in renal function, 498
- influence of position, 498
- risk factors for vascular calcification, 88
- salt preference in pregnant hypertensive rats, 898
- urinary kallikrein excretion in pregnancy, 894

Hypotension, alpha and beta-adrenoceptor regulation during haemodialysis, 259

Hypothalamus, diminished function in uraemia, 1119

IgA
- ethylene oxide specific, 187
- nephropathy
  - antibody idiootype, 705
  - cirrhosis, 784
  - dietary immune complexes, 710
  - effect of tonsillectomy, 800
- glomerular complement deposition, 763
- macrophages, 819
- malignant hypertension, 875
- pregnancy, 431, 473, 482
- prognostic factors, 715
- rate of progression, 715

IgG, peritoneal dialysate effluent and peritonitis, 401

Immune complexes, IgA nephropathy, 710
- deficiency
  - association with impaired lipid peroxidation, 139
  - in haemodialysis, 139
- function, essential mixed cryoglobulinemia, 759
- reactions, loin pain haematuria syndrome, 796

Immunoadsorption, treatment in experimental Goodpasture's syndrome, 736

Immunoblotting of target antigens in Goodpasture's syndrome, 746

Immunological activity, neopterin levels in serum and urine, 672
- monitoring, neopterin, 665
Loin pain haematuria syndrome, intradermal skin testing, 796
Lymphocyte function in chronic renal failure, 941
influence on hepatitis vaccination, 941
uraemia, 932
Lymphocytotoxic antibodies, transplant survival, 589
Lysosomes, aminoglycoside toxicity, 962
Macrophages
IgA nephropathy, 819
neopterin concentrations during rejection, 665, 672
Magnesium carbonate, phosphate binder, 1229
optimum dialysate concentration, 97
Malignancy analgesic nephropathy, 987
in chronic renal failure, 286
urinary tract in analgesic nephropathy, 979
Mefenamic acid nephropathy, 991
Membrane biocompatibility, 164, 196, 223, 225
effects of sterilization procedures, 212
leucocyte elastase as a marker, 202, 212
Membranes convective mass transport, 155
effect on aluminium removal, 386
sieving, 155
Membranous glomerulonephritis cationic IgG, 773
renal effects of pregnancy, 473
T cell subsets, 819
treatment, 819
urinary complement excretion, 790
Mercury, glomerulonephritis, 685
Mesangiocapillary glomerulonephritis reduction in annual incidence, 730
renal factors in pregnancy, 473
Mesangium, kinetics of aggregated IgG, 767
Methotrexate, nephrotoxicity, 1025
Methylhistidine, urinary excretion in renal failure, 1115
Minimal change nephropathy experimental adriamycin induced, 927
immune responses, 813
Mitomycin, experimentally induced renal damage, 1020

Lead in haemodialysis, 276
plasma values in CAPD patients, 410
Leucocyte activation during haemodialysis, 207
Leucopenia acute renal failure, 202
dialysis induced and effect of naftamstat, 334
low temperature dialysis, 216
Leucothrienes, release during haemodialysis, 163
Lipid metabolism, chronic renal failure, 1129
Lipids, effect of L-carnitine in haemodialysis patients, 121
Lipoprotein, chronic renal failure, 1129
Lithium glomerulonephritis, 686
placental transfer causing neonatal diabetes insipidus, 1017

Kallikrein mediator of progression in glomerular disease, 1057
urinary excretion in pregnancy-induced hypertension, 894
Keto-analogues, infusion and GFR, 917
Kinin, mediator of progression in glomerular disease, 1057

Iron metabolism, effect of DFO, 374
overload, Yersina enterocolitica bacteremia, 283

Immunosuppression pregnancy, 452
regimen and transplant survival, 590
retroplacential gamma globulin, 619
Indium labelled platelets in diagnosis of acute graft rejection and Cyclosporin A nephrotoxicity, 1183
Insulin, response to glucagon in uraemia, 1067
Interleukin I release during haemodialysis, 158, 165, 192, 207
Interleukin II uraemia, 932
Interstitial nephritis drug induced, 977
mefenamic acid induced, 991
paediatric registry report details, 59–65
Iron metabolism, effect of DFO, 374
overload, Yersina enterocolitica bacteremia, 283

Kallikrein mediator of progression in glomerular disease, 1057
urinary excretion in pregnancy-induced hypertension, 894
Keto-analogues, infusion and GFR, 917
Kinin, mediator of progression in glomerular disease, 1057

Lead in haemodialysis, 276
plasma values in CAPD patients, 410
Leucocyte activation during haemodialysis, 207
Leucopenia acute renal failure, 202
dialysis induced and effect of naftamstat, 334
low temperature dialysis, 216
Leucothrienes, release during haemodialysis, 163
Lipid metabolism, chronic renal failure, 1129
Lipids, effect of L-carnitine in haemodialysis patients, 121
Lipoprotein, chronic renal failure, 1129
Lithium glomerulonephritis, 686
placental transfer causing neonatal diabetes insipidus, 1017

Lymphocyte function in chronic renal failure, 941
influence on hepatitis vaccination, 941
uraemia, 932
Lymphocytotoxic antibodies, transplant survival, 589
Lysosomes, aminoglycoside toxicity, 962

Macrophages
IgA nephropathy, 819
neopterin concentrations during rejection, 665, 672
Magnesium carbonate, phosphate binder, 1229
optimum dialysate concentration, 97
Malignancy analgesic nephropathy, 987
in chronic renal failure, 286
urinary tract in analgesic nephropathy, 979
Mefenamic acid nephropathy, 991
Membrane biocompatibility, 164, 196, 223, 225
effects of sterilization procedures, 212
leucocyte elastase as a marker, 202, 212
Membranes convective mass transport, 155
effect on aluminium removal, 386
sieving, 155
Membranous glomerulonephritis cationic IgG, 773
renal effects of pregnancy, 473
T cell subsets, 819
treatment, 819
urinary complement excretion, 790
Mercury, glomerulonephritis, 685
Mesangiocapillary glomerulonephritis reduction in annual incidence, 730
renal factors in pregnancy, 473
Mesangium, kinetics of aggregated IgG, 767
Methotrexate, nephrotoxicity, 1025
Methylhistidine, urinary excretion in renal failure, 1115
Minimal change nephropathy experimental adriamycin induced, 927
immune responses, 813
Mitomycin, experimentally induced renal damage, 1020

1246
Monoclonal antibodies
glomerular studies in microscopic polyarteritis, 752
OKT3 antibody in the treatment of transplant rejection, 677
transplant rejection and endothelial cell antigens, 627
Monocyte function, essential mixed cryoglobulinaemia, 759
Monocytes, role in haemodialysis complications, 158, 241
Morphine, renal metabolism, 1109
Motor nerve conduction velocity, suitability for assessing neuropathy, 1167
Myocardium, adrenergic receptor responses in uraemia, 901

Nafamstat, anticoagulant for bleeding risk dialysis patients, 334
Natural killer cells, phenotype in long-term transplant recipients, 614
Neo-antigens, glomerular deposition, 819
Neonatal acute renal failure, 1187
Neopterin
graft monitoring, 665
urine and serum after renal transplantation and rejection, 665, 672
Nephrolithiasis, water quality and thiazide treatment depends on oxalate restriction, 1159
Nephrotic syndrome
circadian rhythm of plasma cortisol, 1062
pregnancy, 515
Nephrotoxicity
acute renal failure in children, 1193
aminoglycosides, 959
analgesics, 987
cis-platinum, 1087
contrast media, 1033
Cyclosporin A, 535, 540, 546, 561, 571, 609, 1183
and factor VIII R antigen, 566
in heart transplant recipients, 551
in rat tubular cells, 556
experimental mitomycin induced, 1020
methotrexate, 1025
Nifedipine
clearance during haemodialysis, 889
pharmacokinetics in chronic renal failure, 889

Nifedipine (continued)
prevention of acute ischaemic renal failure, 1096
Non-steroidal anti-inflammatory drugs, glomerulonephritis, 687
Nuclear magnetic resonance, acute transplant rejection, 609

Occupational hazards, solvent exposure and glomerular disease, 725
Osteocalcin, effect of 1,25(OH)2D3 in uraemia, 1223
Oxalate
deposition aggravated by Vitamin C, 147
importance of restriction in calcium stone formers, 1159
intestinal absorption, 1163

Pancreas, complications in transplantation, 528
Papillary necrosis, drug induced, 978
Parathyroidectomy, paediatric registry report details, 74–75
Parathyroid hormone, response to calcium carbonate in haemodialysis patients, 83
Penicillamine, glomerulonephritis, 685
Peritoneal loss, proteins in CAPD, 405, 421
Peritonitis
amino acid containing solutions to counteract catabolic effects, 421
fungal, 397
protein loss, 421
Rhodotorula, 397
risk factors during CAPD, 401
Phagocytosis, essential mixed cryoglobulinaemia, 759
Pharmacokinetics, of Nifedipine during haemodialysis, 889
Phenacetin
analgesic nephropathy, 987
metabolites in analgesic nephropathy, 980
Phosphate
binders
aluminium overload, 363
magnesium containing, 97
control by oral magnesium carbonate, 1229
lack of correlation with rate of progression to renal failure, 1148
relationship to 1,25(OH)2D3 in early uraemia, 1124
Pregnancy (continued)

in patients with renal disease, 439
placental lithium transfer, 1017
renal
effects in patients with glomerulonephritis, 473
haemodynamics, 463
salt preference in pregnant hypertensive rats, 898
systemic lupus erythematosus, 447, 487
urinary kallikrein excretion in hypertensive patients, 894
Prolactin, secretion in uraemia, 1119
Prostacyclin, interleukin mediator, 239
Prostaglandin(s)
analgesic nephropathy, 978
anti-diuretic hormone release, 1045
effect of amino acid infusions, 1049
haemodialysis, 235
hypotension, 241
9-ketoreductase activity in normal and diabetes insipidus rats, 862
role in glomerular filtration, 1049
synthesis in isolated glomeruli, 858
urinary excretion
after Felodipine, 1037
in rats with potassium loading, 1042
in response to an acute saline load in dogs, 1054
Protein
dietary restriction and experimentally induced nephropathy, 927
effect of
protein load on GFR, 843
soya protein on experimental renal failure, 921
metabolism
effect of exposure to dialysis membranes in haemodialysis patients treated with calcium carbonate, 223
turnover studies in renal failure, 116
restriction and proteinuria, 1083
Proteinases, urinary excretion in experimental glomerulonephritis, 1103
Proteinuria
effect of dietary protein restriction, 1083
low molecular weight following methotrexate therapy, 1025
tubular
following methotrexate therapy, 1025
proteinuria in Cyclosporin A treated rats, 561
Renal failure

acute (continued)
continuous haemofiltration in neonates, 1187
drug induced, 1002
experimental, 1008, 1012
leucocyte elastase, 202
leucopenia, 202
membrane biocompatibility, 202
preventive administration of
Nifedipine, 1103
prognostic factors, 1002
protective effect of calcium antagonists, 1033
proton magnetic resonance studies in
experimental models, 1008
rhabdomyolysis, 1091
thromboxane antagonism, 1012
chronic
amino acid metabolism, 116
analgesic nephropathy, 979
assessment by 99mTc-Aprotinin renal
seans, 1178
hepatitis vaccination, 941
IgA nephropathy, 875
immune defect early in the course of
disease, 941
immunization against hepatitis B, 1077
impairment of cellular immunity, 937
incidence of malignancy, 286
infection complications, 937
influence of follow-up frequency on
progression, 1153
leucocyte elastase, 202
leucopenia, 202
lipoprotein metabolism, 1129
lymphocyte function, 941
malignant hypertension, 875
membrane biocompatibility, 202
no correlation between rate of pro-
gression and serum phosphate, 1148
pharmacokinetics of Nifedipine, 889
platelet function, 946
pregnancy, 439
separate renal function tests, 1178
seroprophylaxis against hepatitis B, 1077
thyroid function tests as an indicator
of carbohydrate control, 953
urinary cytomegalovirus excretion
following transplantation, 1145
Renal (continued)

failure
  effect of dietary protein restriction, 1083
  kallikrein-kinin system and progressive
deterioration, 1057
  mefenamic acid induced, 991
  progression
    and dietary protein, 921
    of glomerular disease and solvent
  exposure, 725
  in pregnancy in FMF, 478
  risk factors for aminoglycoside toxicity,
  970
function
  abnormal cationic IgG in membranous
  nephropathy, 773
  decline following methotrexate therapy,
  1025
  deterioration in glomerular disease and
  kallikrein-kinin system, 1057
  during pregnancy in IgA nephropathy,
  482
  effect of
    dietary protein restriction, 1083
    protein load on GFR, 843
  pregnancy, 439, 464
    in patients with systemic lupus erythe-
    matosus, 487
  reduced 1,25(OH)₂D₃ in early uraemia,
  1124
  urinary complement excretion in mem-
  branous nephropathy, 790
haemodynamics
  alterations in pregnancy, 493
  pregnancy, 463
  isotope scanning in the diagnosis of renal
  graft rejection, 605
metabolism, morphine, 1109
osteodystrophy
  aseptic bone necrosis following trans-
  plantation, 660
  bone GLA protein as an indicator of
  bone formation rates, 1218
  in patients treated by haemofiltration,
  363
  vitamin D receptor status, 382
plasma flow
  changes on infusion of amino acids or
  keto-analogues, 917
  Felodipine, 1037
  pre-eclampsia, 832

Renin (continued)

  plasma flow, pregnancy, 465
  scanning with *⁹⁹mTc-Aprotinin, 1178
  tubule
    enzyme excretion after cis-platinum
    therapy, 1087
    morphine excretion, 1109
    sodium-hydrogen exchange and influ-
    ence of thyroxine, 865
vascular
  angiotensin II in isolated perfused rat
  kidney, 871
  changes in pregnancy induced hyper-
  tension, 894
  renal vein renin in hypertensive patients,
  880
Renin
  diurnal variation in hypertension, 851
  renal vein concentrations in accelerated
  hypertension, 880
Retroplacental gamma globulin, immuno-
suppression, 619
Reverse osmosis, effect on bone aluminium,
  369
Rhabdomyolysis, acute renal failure, 1091
Rheumatoid factor, during CMV infection,
  655
Rhodotorula, peritonitis, 397
Risk factors, CAPD, 401
Selenium
  deficiency in uraemia, 1134
  plasma values in CAPD patients, 410
Sexual dysfunction, long-term dialysis
  patients, 142
Single needle dialysis, 341
Skin
  no effect of Biotin on skin dryness, 255
testing
    haemodialysis hypersensitivity reactions,
    187
    loin pain haematuria syndrome, 796
Sodium
  angiotensin II effect on excretion in iso-
  lated perfused rat kidney, 871
  citrate, anticoagulation for haemodialysis,
  325
  critical dialysate concentration, 235
effect of acute load on prostaglandin
  excretion in ADH suppressed dogs,
  1054
Sodium (continued)
exaggerated natriuresis in hypertensive pregnant patients, 493
haemodialysis symptomatology, 157, 169
interaction with calcium in hypertensive patients, 884
pregnancy, 467
salt preference in pregnant hypertensive rats, 898
tubular
exchange and influence of thyroxine, 865
transport, effect of Felodipine, 1037
Solvent, exposure and glomerular disease, 688, 725
Solvants, acute renal failure, 1033
Steroid therapy, risk factors in aseptic bone necrosis, 660
Superoxide production, impaired during iron overload, 247
Sympathetic nervous system in haemodialysis patients, 259
Systemic lupus erythematosus
congenital heart block in children, 449
drug induced lupus-like syndrome, 687
outcome of pregnancy, 487
plasma exchange, 699, 1200
pregnancy, 447
protein loss during CAPD, 405

T-cell
antibodies, influence on outcome of transplantation, 622
subsets
changes in haemodialysis, 196
membranous glomerulonephritis, 819
in pregnancy, 515
regulation of autoantibody production in Heymann's nephritis, 127
Temperature, dialysis complement activation and leucopenia, 216
Thromboxane
antagonists, experimental acute renal failure, 1012
synthesis in isolated glomeruli, 858
Thyroid function tests in chronic renal failure, 953
Thyroxine, influence on tubular sodium-hydrogen exchange, 865
Tonsillectomy, IgA nephropathy, 800
Trace elements
chromium in CAPD and haemodialysis patients, 270
Trace elements (continued)
plasma values in CAPD patients, 410
selenium deficiency in uraemia, 1134
Transferrin
indicator of iron metabolism, 374
response to calcium carbonate in haemodialysis patients, 83
Transluminal angioplasty, for AV fistula stenosis, 291
Transplantation
acute rejection, 609
diagnosed by isotope scans, 605
analysis of centre effect, 639
autoantibodies, 635
blood transfusion effect, 809
CAPD as a risk factor, 431
children, paediatric report details, 72–74
combined kidney and pancreas, 523
counselling, 456
Cyclosporin A, 535, 571, 579
dose, 571
nephrotoxicity, 535, 540, 546, 571, 609, 1183
cytomegalovirus
immunization, 630
retinitis, 645
erthrocytosis, 651
flow cytometry, 622
in highly sensitized patients, 635
hypercalcemia treated by diphosphonates, 1233
immunological
factors affecting survivors, 585
monitoring, 672
immunosuppression with retroplacental gamma globulin, 619
1,25(OH)2D3, and plasma calcium, 1212
living donor pancreatic transplantation, 530
locum B cell antibodies, 622
measurement of circulatory immune complexes in CMV infections, 655
monoclonal antibodies in the treatment of rejection, 677
natural killer cells, 614
neopterin in graft monitoring, 672
nuclear magnetic resonance, 609
pancreas, 521
pregnancy, 451
and outcome, 508
renal function changes after renal transplantation, 503
Transplantation (continued)

- rejection
- diagnosis with indium labelled platelets, 1183
- endothelial cell antigens, 627
- risk factors in aseptic bone necrosis, 660
- role of Fc receptor blocking factors, 809
- serum and urinary neopterin levels, 672
- T-cell antibodies, 622
- urinary cytomegalovirus excretion, 1145
- use of FALS cross-matching for renal transplantation, 622

Triglycerides

- chronic renal failure, 1129
- effect of L-carnitine in haemodialysis patients, 121
- risk factors for vascular calcification, 88

Uraemia

- abnormal lipoprotein metabolism, 1129
- adrenergic receptor responsiveness, 111
- amino acid metabolism, 116
- effect of dialysis on neuropathy, 1167
  1,25(OH)₂D₃ on bone GLA protein, 1223
- impaired immune response, 932
- influence of follow-up frequency on progression, 1153
- left ventricular function, 906
- 3-methylhistidine excretion, 1115
- myocardial adrenergic receptors, 901
- neuropathy, effect of dialysis, 1167
- pancreatic B cell secretory function, 1067
- plasma 1,25(OH)₂D₃, 1212
- platelet function, 946
- prolactin disorder, 1119
- reduced 1,25(OH)₂D₃ in early uraemia, 1124
- response to hepatitis B vaccination, 1073
- selenium deficiency, 1134
- Uric acid, pregnancy, 832
- Urinary enzyme, excretion after cisplatinum therapy, 1087

Vaccination

- hepatitis B in chronic renal failure, 941
- Vaccination, uraemic patients, 1073
- Vascular access
  - assessment by haemodynamic studies, 296
  - fistula stenosis, 296
  - single needle dialysis, 341
  - transluminal angioplasty, 291
  - venography, 291
- Vascular calcification, risk factors in haemodialysis, 88
- reactivity, pregnancy, 824
- Vasculitis, immunosuppressive treatment in polyarteritis, 720
- Vibration sensory threshold, suitability for assessing neuropathy, 1167
- Viral infections
  - cytomegalovirus, 655
  - leucocytotoxins, 655
  - retinitis, 645
- rheumatoid factor, 655
- Vitamin, biotin supplements, 255
- Vitamin C, harmful effect in haemodialysis patients, 147
- Vitamin D
  - effect on bone GLA protein in uraemia, 1223
  - extra renal production of 1,25(OH)₂D₃, 1209
  - receptor status in aluminium induced osteomalacia, 382
  - reduced 1,25(OH)₂D₃ in early uraemia, 1124
  - role of 1,25(OH)₂D₃ after transplantation, 1212
- Warm B cell antibodies, influence on outcome of transplantation, 622
- Water, effect of angiotensin II in renal handling, 871
- Weight gain, risk factors in aseptic bone necrosis, 660
- Yersina enterocolitica, bacteraemia in haemodialysis, 283
- Zinc, plasma values in CAPD patients, 410